← Back to headlines
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.
19 Mar, 10:45 — 19 Mar, 10:45
Related Stories
Pathologist Shares Four Simple Rules for Weight Loss
24m ago
British Actress Nikki Sanderson Reveals Abuse Over Pregnancy in Her Forties
28m ago
Study Suggests Syphilis-Like Disease Spread in Ancient Vietnam, Challenging Columbus Theory
33m ago
Azerbaijani Sailor Evacuated from Ship in Constanța Port Due to Medical Emergency
35m ago